FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma

The FDA approved the combination use of nivolumab plus ipilimumab for the treatment of patients with HCC who have been previously treated with sorafenib.

Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news